Abstract
To the Editor: In response to the article by Ross in this issue of the Journal,1 we wish to clarify how the Food and Drug Administration (FDA) reviewed Ketek (telithromycin). Although there are oth...
Cite
CITATION STYLE
APA
Soreth, J., Cox, E., Kweder, S., Jenkins, J., & Galson, S. (2007). Ketek — The FDA Perspective. New England Journal of Medicine, 356(16), 1675–1676. https://doi.org/10.1056/nejmc076135
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free